

Ref: FOI/GS/ID 5974

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

02 March 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Biologics and biosimilar prescribing in Rheumatology.

You asked:

Could you please provide me with the following numbers of patients treated in the last 12 months with the following drugs.

- *Abatacept [Orencia]*
- *Adalimumab [Amgevita]*
- *Adalimumab [Hulio]*
- *Adalimumab [Humira]*
- *Adalimumab [Hyrimoz]*
- *Adalimumab [Imraldi]*
- *Apremilast [Otezla]*
- *Baricitinib [Olumiant]*
- *Brodalumab [Kyntheum]*
- *Certolizumab [Cimzia]*
- *Dimethyl fumarate [Skilarence]*
- *Etanercept [Benepali]*
- *Etanercept [Enbrel]*
- *Etanercept [Erelzi]*
- *Golimumab [Simponi]*
- *Guselkumab [Tremfya]*
- *Infliximab [Flixabi]*
- *Infliximab [Inflectra]*
- *Infliximab [Remicade]*
- *Infliximab [Remsima]*
- *Ixekizumab [Taltz]*
- *Risankizumab [Skyrizi]*
- *Rituximab [MabThera]*

- *Rituximab [Rixathon]*
- *Rituximab [Truxima]*
- *Sarilumab [Kevzara]*
- *Secukinumab [Cosentyx]*
- *Tildrakizumab [Ilumetri]*
- *Tocilizumab [Ro Actemra]*
- *Tofacitinib [Xeljanz]*
- *Upadacitinib [Rinvoq]*
- *Ustekinumab [Stelara]*

Trust response:

- Abatacept [Orencia] 109
- Adalimumab [Amgevita] 0
- Adalimumab [Hulio] 0
- Adalimumab [Humira] 241
- Adalimumab [Hyrimoz] 0
- Adalimumab [Imraldi] 475
- Apremilast [Otezla] 3
- Baricitinib [Olumiant] 27
- Brodalumab [Kyntheum] 0
- Certolizumab [Cimzia] 53
- Dimethyl fumarate [Skilarence] 0
- Etanercept [Benepali] 355
- Etanercept [Enbrel] 47
- Etanercept [Erelzi] 0
- Golimumab [Simponi] 218
- Guselkumab [Tremfya] 0
- Infliximab [Flixabi] 0
- Infliximab [Inflectra] 0
- Infliximab [Remicade] 16
- Infliximab [Remsima] 44
- Ixekizumab [Taltz] 0
- Risankizumab [Skyrizi] 0
- Rituximab [MabThera] 8
- Rituximab [Rixathon] 0
- Rituximab [Truxima] 128
- Sarilumab [Kevzara] 1
- Secukinumab [Cosentyx] 112
- Tildrakizumab [Ilumetri] 0
- Tocilizumab [Ro Actemra] 113
- Tofacitinib [Xeljanz] 44
- Upadacitinib [Rinvoq] 0
- Ustekinumab [Stelara] 4